Big pharma sees opportunity in Russia

Russian drug manufacturing is getting a shot in the arm as big pharma makes a play to become entrenched in-country. Investing in local drugmakers provides a convenient workaround to import complexities, reports

Building and buying facilities are the chief means. Among those in on the secret: Nycomed, Novo Nordisk, AstraZeneca and Novartis, says Reuters, along with a half-dozen others are reportedly considering the idea. They are after a piece of the projected 2010 mid-double-digit percentage growth of the Russian pharma market, an appealing contrast to the global projection of 4 percent to 6 percent.

The Association of International Pharmaceutical Manufacturers in Russia expects global drugmakers to drop a combined $1 billion on setting up local production.  

- see the story
- here's the Reuters rundown of players

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.